1. Home
  2. NVO vs GS Comparison

NVO vs GS Comparison

Compare NVO & GS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NVO
  • GS
  • Stock Information
  • Founded
  • NVO 1923
  • GS 1869
  • Country
  • NVO Denmark
  • GS United States
  • Employees
  • NVO N/A
  • GS N/A
  • Industry
  • NVO Biotechnology: Biological Products (No Diagnostic Substances)
  • GS Investment Bankers/Brokers/Service
  • Sector
  • NVO Health Care
  • GS Finance
  • Exchange
  • NVO Nasdaq
  • GS Nasdaq
  • Market Cap
  • NVO 278.0B
  • GS 225.6B
  • IPO Year
  • NVO N/A
  • GS 1999
  • Fundamental
  • Price
  • NVO $55.81
  • GS $786.94
  • Analyst Decision
  • NVO Buy
  • GS Buy
  • Analyst Count
  • NVO 7
  • GS 14
  • Target Price
  • NVO $98.00
  • GS $664.69
  • AVG Volume (30 Days)
  • NVO 14.9M
  • GS 1.7M
  • Earning Date
  • NVO 11-05-2025
  • GS 10-14-2025
  • Dividend Yield
  • NVO 2.24%
  • GS 2.05%
  • EPS Growth
  • NVO 24.25
  • GS 45.80
  • EPS
  • NVO 3.93
  • GS 45.34
  • Revenue
  • NVO $49,108,936,497.00
  • GS $54,794,000,000.00
  • Revenue This Year
  • NVO $10.01
  • GS $12.38
  • Revenue Next Year
  • NVO $9.93
  • GS $4.90
  • P/E Ratio
  • NVO $13.90
  • GS $17.21
  • Revenue Growth
  • NVO 20.91
  • GS 12.06
  • 52 Week Low
  • NVO $45.05
  • GS $439.38
  • 52 Week High
  • NVO $138.22
  • GS $793.17
  • Technical
  • Relative Strength Index (RSI)
  • NVO 51.25
  • GS 68.64
  • Support Level
  • NVO $53.55
  • GS $727.15
  • Resistance Level
  • NVO $55.24
  • GS $793.17
  • Average True Range (ATR)
  • NVO 1.13
  • GS 14.71
  • MACD
  • NVO 0.24
  • GS 3.80
  • Stochastic Oscillator
  • NVO 69.52
  • GS 91.60

About NVO Novo Nordisk A/S

With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

About GS Goldman Sachs Group Inc. (The)

Goldman Sachs is a storied financial institution, founded in 1869 and best known for its role as a leading global investment bank. The firm has a sprawling reach across global financial centers and has been the leading provider of global merger and acquisition advisory services, by revenue, for the past 20 years. Since the global financial crisis, Goldman has expanded its offerings into more stable fee-based businesses like asset and wealth management, which comprised roughly 30% of post-provision revenue at the end of 2024. The bank holding company generates revenue from investment banking, global market making and trading, lending, asset management, wealth management, and a small and declining portfolio of consumer credit card loans.

Share on Social Networks: